IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4340300
  • Report
  • 81 pages
  • P&S Market Research
1 of 3
Pipeline Overview

Immunoglobulin A Nephropathy, also known as IgA nephropathy (IgAN) or Berger’s disease, is a kidney disorder that arises when IgA builds up in the kidneys, resulting in inflammation which causes damage to kidney tissues. IgA is an immunoglobulin A antibody produced by immune system for body protection from foreign substances such as viruses or bacteria. Production of IgA deposits damages the glomeruli and this results in blood and protein in urine. This progresses over time and eventually results in end stage renal disease (ESRD).

IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria, leakage of protein in urine and hematuria, leakage of blood in urine. These symptoms can be observed by naked eyes as the urine color changes in both the conditions. The other signs and symptoms include high blood pressure, dry skin, feeling tired, nausea, little urination, weight loss, appetite loss and sleeping problems.

IgA nephropathy does not have a specific treatment, since when the kidneys get damaged they cannot be repaired. So the only treatment available is to prevent or delay ESRD. The process of kidney damage can be slowed down by the use of fish oil supplements, immunosuppressive drugs, corticosteroids angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors.

Pipeline Analysis

As of March 2017, the IgA nephropathy pipeline comprises of approximately 12 drug candidates in different stages of development.

Competitive Landscape

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
  • Market Forecast - Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Iga Nephropathy Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Target
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Company

5. Iga Nephropathy Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Pre-Clinical: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Strategic Development
5.3.4 Designation
5.3.5 Grants
5.3.6 Patent
5.3.7 Technology
5.4 Inactive: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Clinical Trials
5.4.4 Clinical Results
5.4.5 Strategic Development
5.4.6 Designation
5.4.7 Grants
5.4.8 Patent
5.4.9 Technology
5.5 Discontinued: Drug Profiles
5.5.1 Pre-Clinical Study
5.5.2 Pre-Clinical Results
5.5.3 Clinical Trials
5.5.4 Clinical Results
5.5.5 Strategic Development
5.5.6 Designation
5.5.7 Grants
5.5.8 Patent
5.5.9 Technology

6 Competitive Landscape
6.1 Key Players Benchmarking For Iga Nephropathy Drug Candidates
6.2 Swot Analysis Of Iga Nephropathy Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Iga Nephropathy, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Inactive Drug Candidates
Clinical Trials Of Inactive Drug Candidates
Description Of Discontinued Drug Candidates
Clinical Trials Of Discontinued Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For The Iga Nephropathy Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participant
Breakdown Of Primary Research Respondents, By Company Type
Number Of Iga Nephropathy Drug Candidates Under Development (2017)
Iga Nephropathy Pipeline Split, By Target (2017)
Iga Nephropathy Pipeline Split, By Route Of Administration (2017)
Key Players Benchmarking For Iga Nephropathy Drug Candidates
Swot Analysis Of Iga Nephropathy Therapeutics Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll